In summary, this study demonstrated the correlation between DNA methylation and the effectiveness of EGFR inhibitors, and suggested that DNA methylation might be one of the important regulatory factors affecting the sensitivity of EGFR inhibitors in lung cancer patients. This evidence concerns the gene EGFR and lung cancer.